Prescription drug · ANDA
Erlotinib NDC 63304-135
Erlotinib 150 mg/1 · Tablet, Film coated · Oral · Sun Pharmaceutical Industries, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 63304-135-11 | 63304013511 | 3 BLISTER PACK in 1 CARTON (63304-135-11) / 10 TABLET, FILM COATED in 1 BLISTER PACK (63304-135-31)Marketed from Nov 5, 2019 | |
| 63304-135-30 | 63304013530 | 30 TABLET, FILM COATED in 1 BOTTLE (63304-135-30)Marketed from Nov 5, 2019 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Erlotinib
- Generic name (nonproprietary)
- erlotinib
- Active ingredients
- Erlotinib — 150 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 210300
- Marketing start
- Listing expires
- Other FDA classes
- Protein Kinase Inhibitors (Mechanism)
- Identifiers
- Product ID 63304-135_c160713b-c06f-49b4-80ea-fc1afb030b81SPL ID c160713b-c06f-49b4-80ea-fc1afb030b81SPL set ID e36fa076-e23b-437f-bbd2-0433ce333175RxCUI 603203, 603206, 603208UNII J4T82NDH7EUPC 0363304095302
- Pharmacologic class
- Kinase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N463304013511followed by a unit qualifier and the quantityPackage 63304-0135-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Erlotinib tablets are kinase inhibitors indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. (1.1) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. (1.2) Limitations of Use : • Safety and efficacy of erlotinib tablets have not been established in patients with NSCLC whose tumo…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 210300
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.